Bulgaria - Sofia: Pharmaceutical products

Release

ID
ocds-pyfy63:2019-419190:2019-419190
Date
2019-09-06
Language
BG
Tags
tender

Release in JSON

Process

ID (OCID)
ocds-pyfy63:2019-419190
Releases
2019-09-06 (ocds-pyfy63:2019-419190:2019-419190)
2019-09-27 (ocds-pyfy63:2019-419190:2019-454592)
2019-11-07 (ocds-pyfy63:2019-419190:2019-527555)
2020-07-14 (ocds-pyfy63:2019-419190:2020-329263)
2020-09-07 (ocds-pyfy63:2019-419190:2020-418032)
2020-10-13 (ocds-pyfy63:2019-419190:2020-482337)
2020-10-14 (ocds-pyfy63:2019-419190:2020-484943)
2020-10-14 (ocds-pyfy63:2019-419190:2020-484951)
2020-10-19 (ocds-pyfy63:2019-419190:2020-493274)
2020-10-26 (ocds-pyfy63:2019-419190:2020-507481)
2020-10-26 (ocds-pyfy63:2019-419190:2020-507585)
2020-10-27 (ocds-pyfy63:2019-419190:2020-510105)
2020-11-02 (ocds-pyfy63:2019-419190:2020-521537)
2020-11-04 (ocds-pyfy63:2019-419190:2020-526960)
2020-11-06 (ocds-pyfy63:2019-419190:2020-530636)
2020-11-06 (ocds-pyfy63:2019-419190:2020-530666)
2020-11-06 (ocds-pyfy63:2019-419190:2020-530902)
2020-11-06 (ocds-pyfy63:2019-419190:2020-530937)
2020-11-13 (ocds-pyfy63:2019-419190:2020-543818)
2020-11-13 (ocds-pyfy63:2019-419190:2020-543843)
2020-11-13 (ocds-pyfy63:2019-419190:2020-543974)
2020-11-13 (ocds-pyfy63:2019-419190:2020-543975)
2020-11-20 (ocds-pyfy63:2019-419190:2020-557296)
2020-11-20 (ocds-pyfy63:2019-419190:2020-557321)
2020-11-23 (ocds-pyfy63:2019-419190:2020-561618)
2020-11-25 (ocds-pyfy63:2019-419190:2020-566707)
2020-11-27 (ocds-pyfy63:2019-419190:2020-570469)
2020-11-27 (ocds-pyfy63:2019-419190:2020-570744)
2020-11-30 (ocds-pyfy63:2019-419190:2020-574978)
2020-11-30 (ocds-pyfy63:2019-419190:2020-575007)
2020-12-01 (ocds-pyfy63:2019-419190:2020-577356)
2020-12-01 (ocds-pyfy63:2019-419190:2020-577441)
2020-12-07 (ocds-pyfy63:2019-419190:2020-587989)
2020-12-07 (ocds-pyfy63:2019-419190:2020-588011)
2020-12-07 (ocds-pyfy63:2019-419190:2020-588022)
2020-12-07 (ocds-pyfy63:2019-419190:2020-588041)
2020-12-07 (ocds-pyfy63:2019-419190:2020-588045)
2020-12-07 (ocds-pyfy63:2019-419190:2020-588046)
2020-12-07 (ocds-pyfy63:2019-419190:2020-588048)
2020-12-07 (ocds-pyfy63:2019-419190:2020-588050)
2020-12-08 (ocds-pyfy63:2019-419190:2020-590701)
2020-12-08 (ocds-pyfy63:2019-419190:2020-590704)
2020-12-08 (ocds-pyfy63:2019-419190:2020-590711)
2020-12-08 (ocds-pyfy63:2019-419190:2020-590713)
2020-12-11 (ocds-pyfy63:2019-419190:2020-597028)
2020-12-11 (ocds-pyfy63:2019-419190:2020-597240)
2020-12-11 (ocds-pyfy63:2019-419190:2020-597307)
2020-12-18 (ocds-pyfy63:2019-419190:2020-611659)
2020-12-18 (ocds-pyfy63:2019-419190:2020-611709)
2020-12-18 (ocds-pyfy63:2019-419190:2020-612049)
2020-12-21 (ocds-pyfy63:2019-419190:2020-617176)
2020-12-21 (ocds-pyfy63:2019-419190:2020-617200)
2020-12-21 (ocds-pyfy63:2019-419190:2020-617202)
2020-12-21 (ocds-pyfy63:2019-419190:2020-617203)
2020-12-21 (ocds-pyfy63:2019-419190:2020-617204)
2020-12-21 (ocds-pyfy63:2019-419190:2020-617205)
2020-12-21 (ocds-pyfy63:2019-419190:2020-617206)
2020-12-21 (ocds-pyfy63:2019-419190:2020-617209)
2020-12-21 (ocds-pyfy63:2019-419190:2020-617210)
2020-12-21 (ocds-pyfy63:2019-419190:2020-617211)
2020-12-23 (ocds-pyfy63:2019-419190:2020-624423)
2020-12-23 (ocds-pyfy63:2019-419190:2020-624427)
2020-12-23 (ocds-pyfy63:2019-419190:2020-624428)
2020-12-23 (ocds-pyfy63:2019-419190:2020-624431)
2020-12-23 (ocds-pyfy63:2019-419190:2020-624432)
2020-12-23 (ocds-pyfy63:2019-419190:2020-624433)
2020-12-24 (ocds-pyfy63:2019-419190:2020-629733)
2020-12-24 (ocds-pyfy63:2019-419190:2020-629734)
2020-12-24 (ocds-pyfy63:2019-419190:2020-629741)
2020-12-24 (ocds-pyfy63:2019-419190:2020-629746)
2020-12-24 (ocds-pyfy63:2019-419190:2020-629753)
2021-01-08 (ocds-pyfy63:2019-419190:2021-005432)
2021-01-08 (ocds-pyfy63:2019-419190:2021-005436)
2021-01-11 (ocds-pyfy63:2019-419190:2021-009231)
2021-01-11 (ocds-pyfy63:2019-419190:2021-009238)
2021-01-11 (ocds-pyfy63:2019-419190:2021-009433)
2021-01-12 (ocds-pyfy63:2019-419190:2021-011045)
2021-01-12 (ocds-pyfy63:2019-419190:2021-011144)
2021-01-18 (ocds-pyfy63:2019-419190:2021-021880)
2021-01-18 (ocds-pyfy63:2019-419190:2021-021902)
2021-01-29 (ocds-pyfy63:2019-419190:2021-044907)
2021-01-29 (ocds-pyfy63:2019-419190:2021-044916)
2021-01-29 (ocds-pyfy63:2019-419190:2021-045054)
2021-02-03 (ocds-pyfy63:2019-419190:2021-055084)
2021-02-03 (ocds-pyfy63:2019-419190:2021-055087)
2021-02-12 (ocds-pyfy63:2019-419190:2021-072562)
2021-02-12 (ocds-pyfy63:2019-419190:2021-072705)
2021-02-16 (ocds-pyfy63:2019-419190:2021-079500)
2021-02-16 (ocds-pyfy63:2019-419190:2021-079563)
2021-02-26 (ocds-pyfy63:2019-419190:2021-098121)
2021-02-26 (ocds-pyfy63:2019-419190:2021-098122)
2021-03-05 (ocds-pyfy63:2019-419190:2021-111141)
2021-03-05 (ocds-pyfy63:2019-419190:2021-111144)
2021-03-10 (ocds-pyfy63:2019-419190:2021-120226)
2021-03-10 (ocds-pyfy63:2019-419190:2021-120228)
2021-03-15 (ocds-pyfy63:2019-419190:2021-128229)
2021-03-15 (ocds-pyfy63:2019-419190:2021-128254)
2021-03-15 (ocds-pyfy63:2019-419190:2021-128292)
2021-03-15 (ocds-pyfy63:2019-419190:2021-128318)
2021-03-15 (ocds-pyfy63:2019-419190:2021-128328)
2021-03-15 (ocds-pyfy63:2019-419190:2021-128331)
2021-03-16 (ocds-pyfy63:2019-419190:2021-130731)
2021-03-22 (ocds-pyfy63:2019-419190:2021-141272)
2021-03-22 (ocds-pyfy63:2019-419190:2021-141273)
2021-03-24 (ocds-pyfy63:2019-419190:2021-146453)
2021-03-24 (ocds-pyfy63:2019-419190:2021-146454)
2021-03-24 (ocds-pyfy63:2019-419190:2021-146481)
2021-03-24 (ocds-pyfy63:2019-419190:2021-146482)
2021-03-24 (ocds-pyfy63:2019-419190:2021-146483)
2021-03-31 (ocds-pyfy63:2019-419190:2021-159913)
2021-04-09 (ocds-pyfy63:2019-419190:2021-174944)
2021-04-09 (ocds-pyfy63:2019-419190:2021-175310)
2021-04-09 (ocds-pyfy63:2019-419190:2021-175311)
2021-04-12 (ocds-pyfy63:2019-419190:2021-178186)
2021-04-23 (ocds-pyfy63:2019-419190:2021-201489)
2021-05-10 (ocds-pyfy63:2019-419190:2021-232820)
2021-05-10 (ocds-pyfy63:2019-419190:2021-232841)
2021-05-10 (ocds-pyfy63:2019-419190:2021-232928)
2021-05-12 (ocds-pyfy63:2019-419190:2021-238104)
2021-05-12 (ocds-pyfy63:2019-419190:2021-238110)
2021-05-14 (ocds-pyfy63:2019-419190:2021-242359)
2021-05-17 (ocds-pyfy63:2019-419190:2021-247194)
2021-05-18 (ocds-pyfy63:2019-419190:2021-249307)
2021-05-18 (ocds-pyfy63:2019-419190:2021-249308)
2021-05-18 (ocds-pyfy63:2019-419190:2021-249325)
2021-05-19 (ocds-pyfy63:2019-419190:2021-250786)
2021-05-21 (ocds-pyfy63:2019-419190:2021-254995)
2021-05-21 (ocds-pyfy63:2019-419190:2021-254997)
2021-05-21 (ocds-pyfy63:2019-419190:2021-255112)
2021-05-28 (ocds-pyfy63:2019-419190:2021-266989)
2021-05-28 (ocds-pyfy63:2019-419190:2021-267260)
2021-05-31 (ocds-pyfy63:2019-419190:2021-270766)
2021-06-14 (ocds-pyfy63:2019-419190:2021-296830)
2021-06-15 (ocds-pyfy63:2019-419190:2021-299438)
2021-06-15 (ocds-pyfy63:2019-419190:2021-299469)
2021-06-15 (ocds-pyfy63:2019-419190:2021-299470)
2021-06-15 (ocds-pyfy63:2019-419190:2021-299487)
2021-06-15 (ocds-pyfy63:2019-419190:2021-299503)
2021-06-21 (ocds-pyfy63:2019-419190:2021-310069)
2021-06-21 (ocds-pyfy63:2019-419190:2021-310070)
2021-06-25 (ocds-pyfy63:2019-419190:2021-319090)
2021-06-25 (ocds-pyfy63:2019-419190:2021-319224)
2021-06-30 (ocds-pyfy63:2019-419190:2021-328351)
2021-06-30 (ocds-pyfy63:2019-419190:2021-328357)
2021-06-30 (ocds-pyfy63:2019-419190:2021-328360)
2021-07-02 (ocds-pyfy63:2019-419190:2021-331968)
2021-07-02 (ocds-pyfy63:2019-419190:2021-332193)
2021-07-02 (ocds-pyfy63:2019-419190:2021-332283)
2021-07-14 (ocds-pyfy63:2019-419190:2021-356304)
2021-07-14 (ocds-pyfy63:2019-419190:2021-356307)
2021-07-16 (ocds-pyfy63:2019-419190:2021-360529)
2021-07-19 (ocds-pyfy63:2019-419190:2021-364843)
2021-07-19 (ocds-pyfy63:2019-419190:2021-364844)
2021-07-19 (ocds-pyfy63:2019-419190:2021-364866)
2021-07-19 (ocds-pyfy63:2019-419190:2021-364867)
2021-07-19 (ocds-pyfy63:2019-419190:2021-364868)
2021-07-20 (ocds-pyfy63:2019-419190:2021-367011)
2021-07-27 (ocds-pyfy63:2019-419190:2021-380201)
2021-07-28 (ocds-pyfy63:2019-419190:2021-382801)
2021-07-28 (ocds-pyfy63:2019-419190:2021-382962)
2021-07-28 (ocds-pyfy63:2019-419190:2021-382963)
2021-07-28 (ocds-pyfy63:2019-419190:2021-382964)
2021-07-28 (ocds-pyfy63:2019-419190:2021-382966)
2021-07-30 (ocds-pyfy63:2019-419190:2021-386890)
2021-07-30 (ocds-pyfy63:2019-419190:2021-386893)
2021-07-30 (ocds-pyfy63:2019-419190:2021-386922)
2021-08-03 (ocds-pyfy63:2019-419190:2021-393674)
2021-08-03 (ocds-pyfy63:2019-419190:2021-393678)
2021-08-04 (ocds-pyfy63:2019-419190:2021-396563)
2021-08-10 (ocds-pyfy63:2019-419190:2021-406738)
2021-08-13 (ocds-pyfy63:2019-419190:2021-412126)
2021-08-16 (ocds-pyfy63:2019-419190:2021-415911)
2021-08-17 (ocds-pyfy63:2019-419190:2021-418020)
2021-08-20 (ocds-pyfy63:2019-419190:2021-423334)
2021-08-24 (ocds-pyfy63:2019-419190:2021-428730)
2021-08-30 (ocds-pyfy63:2019-419190:2021-437371)
2021-09-01 (ocds-pyfy63:2019-419190:2021-441691)
2021-09-01 (ocds-pyfy63:2019-419190:2021-441772)
2021-09-01 (ocds-pyfy63:2019-419190:2021-441773)
2021-09-03 (ocds-pyfy63:2019-419190:2021-445355)
2021-09-03 (ocds-pyfy63:2019-419190:2021-445362)
2021-09-03 (ocds-pyfy63:2019-419190:2021-445372)
2021-09-03 (ocds-pyfy63:2019-419190:2021-445415)
2021-09-03 (ocds-pyfy63:2019-419190:2021-445434)
2021-09-03 (ocds-pyfy63:2019-419190:2021-445497)
2021-09-03 (ocds-pyfy63:2019-419190:2021-445498)
2021-09-06 (ocds-pyfy63:2019-419190:2021-449008)
2021-09-06 (ocds-pyfy63:2019-419190:2021-449019)
2021-09-06 (ocds-pyfy63:2019-419190:2021-449042)
2021-09-06 (ocds-pyfy63:2019-419190:2021-449043)
2021-09-06 (ocds-pyfy63:2019-419190:2021-449129)
2021-09-06 (ocds-pyfy63:2019-419190:2021-449130)
2021-09-13 (ocds-pyfy63:2019-419190:2021-461082)
2021-09-13 (ocds-pyfy63:2019-419190:2021-461371)
2021-09-13 (ocds-pyfy63:2019-419190:2021-461386)
2021-09-13 (ocds-pyfy63:2019-419190:2021-461387)
2021-09-14 (ocds-pyfy63:2019-419190:2021-463441)
2021-09-14 (ocds-pyfy63:2019-419190:2021-463442)
2021-09-17 (ocds-pyfy63:2019-419190:2021-469293)
2021-09-21 (ocds-pyfy63:2019-419190:2021-475996)
2021-09-22 (ocds-pyfy63:2019-419190:2021-478610)
2021-09-24 (ocds-pyfy63:2019-419190:2021-482176)
2021-09-24 (ocds-pyfy63:2019-419190:2021-482177)
2021-09-24 (ocds-pyfy63:2019-419190:2021-482439)
2021-09-28 (ocds-pyfy63:2019-419190:2021-488775)
2021-10-01 (ocds-pyfy63:2019-419190:2021-495544)
2021-10-05 (ocds-pyfy63:2019-419190:2021-502280)
2021-10-08 (ocds-pyfy63:2019-419190:2021-508615)
2021-10-08 (ocds-pyfy63:2019-419190:2021-509022)
2021-10-15 (ocds-pyfy63:2019-419190:2021-522798)
2021-10-19 (ocds-pyfy63:2019-419190:2021-529998)
2021-10-20 (ocds-pyfy63:2019-419190:2021-532566)
2021-10-20 (ocds-pyfy63:2019-419190:2021-532590)
2021-10-22 (ocds-pyfy63:2019-419190:2021-536343)
2021-10-22 (ocds-pyfy63:2019-419190:2021-536346)
2021-10-22 (ocds-pyfy63:2019-419190:2021-537442)
2021-10-27 (ocds-pyfy63:2019-419190:2021-547010)
2021-10-29 (ocds-pyfy63:2019-419190:2021-551866)
2021-10-29 (ocds-pyfy63:2019-419190:2021-551884)
2021-10-29 (ocds-pyfy63:2019-419190:2021-552285)
2021-10-29 (ocds-pyfy63:2019-419190:2021-552290)
2021-11-22 (ocds-pyfy63:2019-419190:2021-595011)
2021-11-26 (ocds-pyfy63:2019-419190:2021-603696)
2021-11-26 (ocds-pyfy63:2019-419190:2021-603697)
2021-11-26 (ocds-pyfy63:2019-419190:2021-603878)
2021-12-01 (ocds-pyfy63:2019-419190:2021-613551)
2021-12-03 (ocds-pyfy63:2019-419190:2021-616737)
2021-12-07 (ocds-pyfy63:2019-419190:2021-624157)
2021-12-10 (ocds-pyfy63:2019-419190:2021-630548)
2021-12-10 (ocds-pyfy63:2019-419190:2021-630550)
2021-12-17 (ocds-pyfy63:2019-419190:2021-644500)
2021-12-20 (ocds-pyfy63:2019-419190:2021-649998)
2021-12-20 (ocds-pyfy63:2019-419190:2021-650005)
2022-01-04 (ocds-pyfy63:2019-419190:2022-002516)
2022-02-02 (ocds-pyfy63:2019-419190:2022-057454)
2022-02-02 (ocds-pyfy63:2019-419190:2022-057458)

Releases in JSON

Tender

Title
Bulgaria - Sofia: Pharmaceutical products
Award criteria
priceOnly
Award criteria details
Lowest price

Award criteria for item 1:
- Price

Award criteria for item 2:
- Price
Award period
2019-10-08 - ?
Eligibility criteria
Suitability:

1. Участниците в обществената поръчка трябва да притежават разрешение за производство, издадено по реда на Закона за лекарствените продукти в хуманната медицина (ЗЛПХМ) (в случаите по чл. 196, ал. 1 от ЗЛПХМ) или за търговия на едро с лекарствени продукти или удостоверение за регистрация за търговия на едро с лекарствени продукти (случаите по чл. 195, ал. 1 и ал. 2 от ЗЛПХМ), или разрешение за внос (случаите по чл. 196, ал. 2 от ЗЛПХМ) — издадени по реда на ЗЛПХМ.Съответствието с поставения критерий се декларира с попълване на част IV, буква „Г“ от еЕЕДОП, като се посочва: номер и дата на издаване на разрешението за производство, издадено по реда на ЗЛПХМ или за търговия на едро с лекарствени продукти или на удостоверението за регистрация за търговия на едро с лекарствени продукти, или на разрешението за внос.На основание чл. 67, ал. 5 и чл. 112, ал. 1, т. 2 от ЗОП документът, който се представя от участника определен за изпълнител, преди да бъде сключено рамково споразумение или при поискване в хода на процедурата е: заверено копие на валидно разрешение за производство, издадено по реда на ЗЛПХМ или за търговия на едро с лекарствени продукти или удостоверение за регистрация за търговия на едро с лекарствени продукти, или разрешение за внос. Възложителят не изисква заверено копие на разрешението или на друг документ, удостоверяващ правото за търговия с лекарствени продукти или разрешение за производство или внос, когато има достъп по служебен път или чрез публичен регистър, или когато същите могат да бъдат осигурени чрез пряк и безплатен достъп до националните бази данни на държавите членки.2. Участниците в обществената поръчка трябва да притежават лицензия, издадена по реда на Закона за контрол на наркотичните вещества и прекурсорите (ЗКНВП), когато участват за доставка на лекарствени продукти, съдържащи наркотични вещества от приложения № 2 и № 3 към чл. 3, т. 2 и т. 3 от Наредбата за класифициране на растенията и веществата като наркотични (важи само за номенклатурите на лекарствени продукти съдържащи наркотични вещества от Приложения № 2 и № 3 към чл. 3, т. 2 и т. 3 от Наредбата за класифициране на растенията и веществата като наркотични).Съответствието с поставения критерий се декларира с попълване на част IV, буква „Г“ от еЕЕДОП, като се посочва: номер и дата на издаване на лицензията, издадена по реда на ЗКНВП за лекарствени продукти, съдържащи наркотични вещества от приложения № 2 и 3 към чл. 3, т. 2 и 3 от Наредбата за класифициране на растенията и веществата като наркотични.На основание чл. 67, ал. 5 и чл. 112, ал. 1, т. 2 от ЗОП документът, който се представя от участника, определен за изпълнител, преди да бъде сключено рамково споразумение или при поискване в хода на процедурата е: заверено копие на валидна лицензия, издадена по реда на ЗКНВП за лекарствени продукти, съдържащи наркотични вещества от Приложения № 2 и 3 към чл. 3, т. 2 и 3 от Наредбата за класифициране на растенията и веществата като наркотични. Възложителят не изисква заверено копие на лицензията по предходното изречение, когато има достъп по служебен път или чрез публичен регистър, или когато същата може да бъде осигурена чрез пряк и безплатен достъп до националните бази данни на държавите членки.

Economic/financial eligibility:

Възложителят не поставя изисквания.

Economic/financial minimum level:

Възложителят не поставя изисквания.

Technical/professional eligibility:

Възложителят не поставя изисквания.

Technical/professional minimum level:

Възложителят не поставя изисквания.
Main procurement category
goods
Procurement method
open
Procurement method details
Open procedure

Participants: 20
Tender period
2019-09-06 - 2019-10-08
Value
1 080 909 890.52 BGN
Minimum value
1 080 909 890.52 BGN

Tender item

ID
ocds-pyfy63:2019-419190:obj:1
Classification
CPV / 33600000
Description
B02BX04, Romiplostim, парентерална, mcg, 1978000; B02BX05 Eltrombopag, перорална твърда, mg, 2545800; B03XA01, erythropoietin (Epoetin alfa), парентерална, IU, 1440363640; B03XA01,Erythropoietin(Epoetin beta), парентерална, IU, 581226800; B03XA01 Erythropoietin(Epoetin zeta) парентерална, IU, 394183200; B03XA02,Darbepoetin alfa, парентерална, mcg, 3047186; B03XA03, Methoxy polyethylene glycol-epoetin beta, парентерална, mcg, 619875; H01CB02, Octreotide, парентерална, mg, 122604 Powder and solvent for suspension for injection; H02AB02, Dexamethasone, парентерална, mg, 11868994; J06BA02 Immunoglobulins, normal human, for intravascular adm., парентерална, mg, 24526250, 50 mg/ml; J06BA02, Immunoglobulins, normal human, for intravascular adm., парентерална, mg, 32838000, 100mg/ml; L01AA01, Cyclophosphamide, парентерална, mg, 39039322; L01AA02, Chlorambucil, перорална твърда, mg, 230212; L01AA06, Ifosfamide, парентерална, mg, 28479000, L01AA09, Bendamustine, парентерална, mg, 1163000; L01AX03, Temozolomide, перорална твърда, mg, 7759180; L01BA04,Pemetrexed, парентерална, mg, 3516200; L01BB02, Mercaptopurine, перорална твърда, mg, 4478600; L01BB05, Fludarabine парентерална, mg, 162300; L01BB06, Clofarabine, парентерална, mg, 18720; L01BB07, Nelarabine, парентерална, mg, 240500; L01BC01, Cytarabine, парентерална, mg, 10835000, Solution for injection 50 mg/ ml; L01BC01, Cytarabine, парентерална, mg, 3000, Suspension for injection 50 mg/ml; L01BC01, Cytarabine, парентерална, mg, 3300000, Solution for injection/infusion 100 mg/ml; L01BC02, Fluorouracil, парентерална, mg, 196701131; L01BC05, Gemcitabine, парентерална, mg, 38262600; L01BC06, Capecitabine, перорална твърда, mg, 846635700; L01BC07, Azacitidine, парентерална, mg, 1669200; L01BC53, Tegafur, Gimeracil, Oteracil, перорална твърда, tabl, 53500,20 mg/5,8 mg/15,8 mg; L01BC59, Trifluridine/Tipiracil, перорална твърда, tabl, 38680, 15 mg/6,14 mg; L01BC59, Trifluridine/Tipiracil, перорална твърда, tabl, 108920, 20 mg/8,19 mg; L01CA04, Vinorelbine, парентерална, mg, 382310; L01CB01, Etoposide, парентерална, mg, 6152528; L01CD01, Paclitaxel, парентерална, mg, 7815272; L01CD02, Docetaxel, парентерална, mg, 2908264; L01CD04, Cabazitaxel, парентерална, mg, 90032; L01DB01, Doxorubicin, парентерална, mg, 274400, Concentrate for solution for infusion; L01DB01, Doxorubicin, парентерална, mg, 127780,Powder, dispersion and solvent for concentrate for dispersion for infusion; L01DB03, Epirubicin, парентерална, mg, 4138050; L01DB06, Idarubicin, парентерална, mg, 26425; L01DB07, Mitoxantrone, парентерална, mg, 48036; L01DB11, Pixantrone, парентерална, mg, 93312; L01XA01, Cisplatin, парентерална, mg, 2667680; L01XA02, Carboplatin, парентерална, mg, 9604450; L01XA03, Oxaliplatin, парентерална, mg, 4881154; L01XC02, Rituximab, парентерална, mg, 6128000, concentrate for solution for infusion МКБ С82,С83,С91,M31; L01XC02, Rituximab, парентерална, mg, 4417000, solution for injection; L01XC03, Trastuzumab, парентерална, mg, 4033140, Powder for concentrate for solution for infusion; L01XC03,Trastuzumab, парентерална, mg, 8816640, Solution for injection; L01XC06, Cetuximab, парентерална, mg, 4154934; L01XC07, Bevacizumab, парентерална, mg, 24423280; L01XC08, Panitumumab, парентерална, mg, 1704120; L01XC11, Ipilimumab, парентерална, mg, 86530; L01XC12, Brentuximab vedotin, парентерална, mg, 114950; L01XC13, Pertuzumab, парентерална, mg, 3571900; L01XC14, Trastuzumab Emtansine, парентерална, mg, 645280; L01XC15, Obinutuzumab, парентерална, mg, 1254000; L01XC17, Nivolumab, парентерална, mg, 639460; L01XC18, Pembrolizumab, парентерална, mg, 1602400; L01XC19, blinatumomab, парентерална, mcg, 22676; L01XC21, Ramucirumab, парентерална, mg, 1324654; L01XC24, Daratumumab, парентерална, mg, 1957000; L01XC26, Inotuzumab ozogamicin, парентерална, mg, 213; L01XC27, olaratumab, парентерална, mg, 1202890; L01XC32, Atezolizumab, парентерална, mg, 7882400; Продължава в раздел II.2.14) Допълнителна информация.

Tender item

ID
ocds-pyfy63:2019-419190:obj:2
Classification
CPV / 33600000
Description
L01XE03, Erlotinib, перорална твърда, mg, 11920500; L01XE04, Sunitinib, перорална твърда, mg, 3616150; L01XE05, Sorafenib, перорална твърда, mg, 68021760; L01XE06, Dasatinib, перорална твърда, mg, 2233200; L01XE07, Lapatinib, перорална твърда, mg, 48462150; L01XE08, Nilotinib, перорална твърда, mg, 161446800; L01XE09, Temsirolimus, парентерална, mg, 70460; L01XE10, Everolimus, перорална твърда, mg, 1291620, 5 mg/10 mg; L01XE12, Vandetanib, перорална твърда, mg, 6419200; L01XE13, Afatinib, перорална твърда, mg, 1683352; L01XE14, Bosutinib, перорална твърда, mg, 10058000; L01XE15, Vemurafenib, перорална твърда, mg, 50198228; L01XE16, Crizotinib, перорална твърда, mg, 11489500; L01XE17, Axitinib, перорална твърда, mg, 417416; L01XE18, Ruxolitinib, перорална твърда, mg, 1160920; L01XE21, Regorafenib, перорална твърда, mg, 7132160; L01XE23, Dabrafenib, перорална твърда, mg, 14592803; L01XE24, Ponatinib, перорална твърда, mg, 672120; L01XE27, Ibrutinib, перорална твърда, mg, 28736400; L01XE33, palbociclib, перорална твърда, mg, 7978075; L01XE35, Osimertinib, перорална твърда, mg, 3307200, L01XE36, alectinib, перорална твърда, mg, 59400000; L01XE11, Pazopanib, перорална твърда, mg, 72451360; L01XX17, Topotecan, парентерална, mg, 20446; L01XX17, Topotecan, перорална твърда, mg, 9350; L01XX19, Irinotecan, парентерална, mg, 3414614; L01XX23, Mitotane, перорална твърда, mg, 19775000; L01XX32, Bortezomib, парентерална, mg, 36813; L01XX35, Anagrelide, перорална твърда, mg, 154138; L01XX41, Eribulin, парентерална, mg, 14762; L01XX43, Vismodegib, перорална твърда, mg, 5825580; L01XX44, Aflibercept, парентерална, mg, 1060100; L01XX45, Carfilzomib, парентерална, mg, 424400; L01XX50, Ixazomib, перорална твърда, mg, 14235; L01XX52, venetoclax, перорална твърда, mg, 12787512; L02BB04, Enzalutamide, перорална твърда, mg, 39388288; L02BX03, Abiraterone, перорална твърда, mg, 205631400; L03AA02, Filgrastim, парентерална, mg, 47632; L03AA13, Pegfilgrastim, парентерална, mg, 70073; L03AA14, Lipegfilgrastim, парентерална, mg, 29038; L03AB04, Interferon alfa-2a, парентерална, MIU, 372844; L03AX03, Mycobacterium bovis BCG, интракавитална, mg, 372575; L03AX16, Plerixafor, парентерална, mg, 2880; L04AD01, Ciclosporin, перорална твърда, mg, 6284522; L04AD01, Ciclosporin, перорална течна, mg, 926000; L01BA01, Methotrexate, парентерална, mg, 7640000, concentrate for solution for infusion; M05BA06, Ibandronic acid, парентерална, mg, 10512, concentrate for solution for infusion; M05BA08, Zoledronic acid, парентерална, mg, 155449; M05BX04, Denosumab, парентерална, mg, 3957240, 120 mg; N02AA01, Morphine, парентерална, mg, 9681084; N02AA01, Morphine, перорална твърда, mg, 52964520; N02AA05, Oxycodone, перорална твърда, mg, 53907236; N02AA08, Dihydrocodeine, перорална твърда, mg, 25232064; N02AA55, Oxycodone, Naloxone, перорална твърда, mg, оxycodone, 30685880, N02AB02, Pethidine, парентерална, mg, 24560413; N02AB03, Fentanyl, перорална твърда, mg, 22607; N02AB03, Fentanyl, трансдермална, mcg/h, 10123137; N02AE01, Buprenorphine, трансдермална, mcg/h, 5410305; N02AX02, Tramadol, парентерална, mg, 62265562; N02AX02, Tramadol, перорална твърда, mg, 63381264; N02AX52, Tramadol, Paracetamol, перорална твърда, tabl, 1181816, 37.5 mg/325 mg; N02AX52, Tramadol, Paracetamol, перорална твърда, tabl, 627230, 75 mg/650 mg; V03AC01, Deferoxamine, парентерална, mg, 1571000; V03AC02, Deferiprone, перорална твърда, mg, 5500000; V03AC02, Deferiprone, перорална течна, mg, 3700000; V03AC03, Deferasirox, перорална твърда, mg, 6241200; V03AF01, Mesna, парентерална, mg, 36844440; V03AF03, Calcium folinate, парентерална, mg, 31037060; L01XX46, Olaparib, перорална твърда, 35972040, Capsule, hard.

Parties

Roles
buyer
Organization name
Ministerstvo na zdraveopazvaneto
Street address
pl. „Sveta Nedelya“ No. 5
Locality
Sofiya
Postal code
1000
Country
BG
Contact name
Rumyana Stavreva
E-mail
rstavreva@mh.government.bg
Phone
+359 29301-314
Fax
+359 29301-451
Website
Link

Organization data Organization in JSON